These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 2386961)

  • 1. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
    Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
    Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
    Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
    Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
    Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
    Melioli G; Margarino G; Scala M; Mereu P; Bertoglio S; Schenone G; Barbaresi M; Machí AM; Santi L; Badellino F
    Laryngoscope; 1992 May; 102(5):572-8. PubMed ID: 1533435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells.
    Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I
    Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
    Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells.
    Morikawa Y; Watanabe S; Kodama T
    Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
    Itoh K; Tilden AB; Balch CM
    J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
    Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
    Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
    Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
    Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
    Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
    J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
    Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
    Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
    Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.